Clinical study of thymalfasin combined with radiotherapy for non-small cell lung cancer / 中国基层医药

ABSTRACT

Objective To discuss the clinical effect of thymalfasin combined with radiotherapy for non -small cell lung cancer (NSCLC).Methods According to digital table,61 patients with NSCLC were randomly assigned to combined therapy group and radiotherapy group.The control group(radiotherapy group)only used radia-tion therapy.The treatment group(combination group)used thymalfasin combined with radiotherapy.The tumor lesion changes,immune indicators and the quality of life were observed.Results The effective rate of the tumor lesion changes in the treatment group was 83.9%,which in the control group was 76.7%(χ2 =0.725,P >0.05)).The levels of CD +4 ,CD +4 /CD +8 in the treatment group were (49.29 ±4.48)%,(1 .91 ±0.44),which were significantly higher than (33.1 7 ±1 .07)%,(1 .38 ±0.48)in the control group (t =1 4.69,5.34,all P <0.05).The improve-ment rate of digestive tract reaction in the treatment group was 74.2%,the body -weight ratio was 38.7%,the increased rate of KPS(karnofsky performance score)was 64.5%,while those of the control group were 23.3%, 1 3.3%,36.7% (χ2 =5.87,6.1 2,3.87,all P <0.05).Conclusion Compared with the use of radiotherapy only, thymalfasin combined with radiotherapy for NSCLC was more effective for patients in tumor lesion response,cell immu-nity and the quality of life.